|
1
|
Susceptibility to exacerbation in chronic obstructive pulmonary disease.
|
N Engl J Med
|
2010
|
15.07
|
|
2
|
Six-minute-walk test in chronic obstructive pulmonary disease: minimal clinically important difference for death or hospitalization.
|
Am J Respir Crit Care Med
|
2012
|
3.44
|
|
3
|
Smoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo- and bupropion-controlled trial with 1-year follow-up.
|
Arch Intern Med
|
2006
|
3.30
|
|
4
|
Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation.
|
Arch Intern Med
|
2006
|
3.30
|
|
5
|
Safety and immunogenicity of a nicotine conjugate vaccine in current smokers.
|
Clin Pharmacol Ther
|
2005
|
2.04
|
|
6
|
Design of the Subpopulations and Intermediate Outcomes in COPD Study (SPIROMICS).
|
Thorax
|
2013
|
1.99
|
|
7
|
Inflammatory biomarkers improve clinical prediction of mortality in chronic obstructive pulmonary disease.
|
Am J Respir Crit Care Med
|
2012
|
1.99
|
|
8
|
A genome-wide association study of COPD identifies a susceptibility locus on chromosome 19q13.
|
Hum Mol Genet
|
2011
|
1.98
|
|
9
|
Effects of sustained-release bupropion among persons interested in reducing but not quitting smoking.
|
Am J Med
|
2004
|
1.76
|
|
10
|
Genome-wide association analysis of blood biomarkers in chronic obstructive pulmonary disease.
|
Am J Respir Crit Care Med
|
2012
|
1.72
|
|
11
|
Bronchodilator responsiveness as a phenotypic characteristic of established chronic obstructive pulmonary disease.
|
Thorax
|
2012
|
1.72
|
|
12
|
Chronic obstructive pulmonary disease biomarker(s) for disease activity needed--urgently.
|
Am J Respir Crit Care Med
|
2010
|
1.66
|
|
13
|
COPD as a lung disease with systemic consequences--clinical impact, mechanisms, and potential for early intervention.
|
COPD
|
2008
|
1.65
|
|
14
|
Gender differences in the management and experience of Chronic Obstructive Pulmonary Disease.
|
Respir Med
|
2004
|
1.37
|
|
15
|
Predicting outcomes from 6-minute walk distance in chronic obstructive pulmonary disease.
|
J Am Med Dir Assoc
|
2011
|
1.28
|
|
16
|
Variable DNA methylation is associated with chronic obstructive pulmonary disease and lung function.
|
Am J Respir Crit Care Med
|
2011
|
1.26
|
|
17
|
Sputum neutrophils as a biomarker in COPD: findings from the ECLIPSE study.
|
Respir Res
|
2010
|
1.26
|
|
18
|
Shotgun proteomic analysis of human-induced sputum.
|
Proteomics
|
2006
|
1.16
|
|
19
|
A randomised trial of fluticasone furoate/vilanterol (50/25 μg; 100/25 μg) on lung function in COPD.
|
Respir Med
|
2013
|
1.12
|
|
20
|
Determinants of airflow obstruction in severe alpha-1-antitrypsin deficiency.
|
Thorax
|
2007
|
1.12
|
|
21
|
Genetics of sputum gene expression in chronic obstructive pulmonary disease.
|
PLoS One
|
2011
|
1.11
|
|
22
|
The COPD Biomarker Qualification Consortium (CBQC).
|
COPD
|
2013
|
1.06
|
|
23
|
Inflammation in COPD: implications for management.
|
Am J Med
|
2012
|
1.00
|
|
24
|
NF-kappaB mediates the survival of human bronchial epithelial cells exposed to cigarette smoke extract.
|
Respir Res
|
2008
|
0.96
|
|
25
|
Identification of lipocalin and apolipoprotein A1 as biomarkers of chronic obstructive pulmonary disease.
|
Am J Respir Crit Care Med
|
2010
|
0.94
|
|
26
|
Diet and vitamin D as risk factors for lung impairment and COPD.
|
Transl Res
|
2013
|
0.94
|
|
27
|
One-year treatment with mometasone furoate in chronic obstructive pulmonary disease.
|
Respir Res
|
2008
|
0.89
|
|
28
|
One-year extension study of ACCORD COPD I: safety and efficacy of two doses of twice-daily aclidinium bromide in patients with COPD.
|
COPD
|
2013
|
0.88
|
|
29
|
The association of plasma biomarkers with computed tomography-assessed emphysema phenotypes.
|
Respir Res
|
2014
|
0.88
|
|
30
|
Vitamin D, vitamin D binding protein, lung function and structure in COPD.
|
Respir Med
|
2013
|
0.84
|
|
31
|
Turning a molecule into a medicine: the development of indacaterol as a novel once-daily bronchodilator treatment for patients with COPD.
|
Drugs
|
2014
|
0.82
|
|
32
|
Using COPD multidimensional indices in routine clinical practice: DOSE meets all criteria.
|
Prim Care Respir J
|
2012
|
0.81
|
|
33
|
Analyzing networks of phenotypes in complex diseases: methodology and applications in COPD.
|
BMC Syst Biol
|
2014
|
0.80
|
|
34
|
Response of vitamin D binding protein and free vitamin D concentrations to vitamin D supplementation in hospitalized premature infants.
|
J Pediatr Endocrinol Metab
|
2015
|
0.76
|
|
35
|
Development of a primary-care tool to assess treatment success in COPD: consensus report from a closed meeting of respiratory and primary-care specialists.
|
Prim Care Respir J
|
2004
|
0.75
|
|
36
|
It's about time--directing our attention toward modifying the course of COPD.
|
Respir Med
|
2008
|
0.75
|